ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.89+0.08 (+2.10%)
Close on Nov 13, 2026Market cap $386.85MP/E –Yield –
ARS Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
ARS Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $30.74M, up 140.8% year over year. For fiscal 2025 it was $13.18M, down 32.7% from the year before. The highest annual figure on record is $24.58M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.18M | -32.7% |
| FY2024 | Dec 31, 2024 | $19.58M | -3.4% |
| FY2023 | Dec 31, 2023 | $20.27M | +10.3% |
| FY2022 | Dec 31, 2022 | $18.38M | -9.4% |
| FY2021 | Dec 31, 2021 | $20.27M | -17.5% |
| FY2020 | Dec 31, 2020 | $24.58M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $18.26M | +563.9% |
| Q2 FY2026 | Jun 30, 2026 | $4.70M | +16.4% |
| Q1 FY2026 | Mar 31, 2026 | $4.34M | +46.9% |
| Q4 FY2025 | Dec 31, 2025 | $3.44M | +13.7% |
| Q3 FY2025 | Sep 30, 2025 | $2.75M | -37.8% |
| Q2 FY2025 | Jun 30, 2025 | $4.04M | -41.5% |
| Q1 FY2025 | Mar 31, 2025 | $2.95M | -43.6% |
| Q4 FY2024 | Dec 31, 2024 | $3.03M | -11.1% |
| Q3 FY2024 | Sep 30, 2024 | $4.42M | +47.3% |
| Q2 FY2024 | Jun 30, 2024 | $6.90M | -5.6% |
| Q1 FY2024 | Mar 31, 2024 | $5.23M | -20.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.40M | -27.7% |
| Q3 FY2023 | Sep 30, 2023 | $3.00M | -22.9% |
| Q2 FY2023 | Jun 30, 2023 | $7.31M | +68.0% |
| Q1 FY2023 | Mar 31, 2023 | $6.55M | +20.8% |
| Q4 FY2022 | Dec 31, 2022 | $4.71M | -70.3% |
| Q3 FY2022 | Sep 30, 2022 | $3.89M | -75.1% |
| Q2 FY2022 | Jun 30, 2022 | $4.35M | -75.5% |
| Q1 FY2022 | Mar 31, 2022 | $5.42M | -55.7% |
| Q4 FY2021 | Dec 31, 2021 | $15.87M | +79.6% |
| Q3 FY2021 | Sep 30, 2021 | $15.64M | +152.3% |
| Q2 FY2021 | Jun 30, 2021 | $17.75M | +246.3% |
| Q1 FY2021 | Mar 31, 2021 | $12.24M | +177.3% |
| Q4 FY2020 | Dec 31, 2020 | $8.84M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.20M | – |
| Q2 FY2020 | Jun 30, 2020 | $5.13M | – |
| Q1 FY2020 | Mar 31, 2020 | $4.41M | – |
See a number that looks wrong?